The subcutaneously administered trastuzumab contains the same monoclonal antibody as the intravenous formulation at a dose of 600 mg per 5-mL vial, plus a recombinant human hyaluronidase, to be used every 3 weeks. The hyaluronidase is used to increase the permeability of the extracellular matrix, allowing for administration of higher volumes and enhanced absorption of the drug.
In March of this year, the FDA approved a subcutaneously administered version of brand-name trastuzumab, Herceptin. The product, trastuzumab and hyaluronidase-oysk, was approved under the brand name Herceptin Hylecta.
The subcutaneously administered trastuzumab contains the same monoclonal antibody as the intravenous formulation at a dose of 600 mg per 5-mL vial, plus a recombinant human hyaluronidase, to be used every 3 weeks. The hyaluronidase is used to increase the permeability of the extracellular matrix, allowing for administration of higher volumes and enhanced absorption of the drug.
On the heels of the approval, researchers have now reported a final analysis of the HannaH trial, a phase 3 study that helped secure the FDA’s approval. In the trial 294 patients with ERBB2—positive early breast cancer were treated with 8 cycles of chemotherapy and subcutaneous trastuzumab, and 297 patients were treated with chemotherapy plus the intravenous trastuzumab. Patients then received another 10 cycles of their assigned trastuzumab in the adjuvant setting for 1 year.
Six-year event-free survival rates were 65% in both arms (hazard ratio [HR], 0.98; 95% CI, 0.74-1.29) and overall survival rates were 84% in both arms (HR, 0.94; 95% CI, 0.61-1.45).
The incidence of adverse events (AEs) was comparable between arms, with 97.6% and 94.6% of patients reporting AEs in the subcutaneous and intravenous groups, respectively. Serious AEs were reported in 21.9% and 15.1% of patients, respectively, and the incidence of cardiac AEs was also similar, at 14.8% and 14.1%, respectively, even for patients in the lowest body-weight quartile.
These data, which support the long-term comparability in terms of efficacy and safety of the subcutaneous trastuzumab versus the intravenous option, will be welcome reassurance for patients and providers who seek to reduce the burden of chair time for lengthy infusions with trastuzumab. The newly approved subcutaneous formulation has also been shown to save on costs in other regulatory territories where the drug is already widely in use.
For developers of intravenously administered biosimilar products, however, these results may be cause for business-related concern; in the United States, 5 biosimilars of trastuzumab have been approved (Ontruzant, Herzuma, Kanjinti, Ogivri, and Trazimera), and the first of these agents are expected to launch as early as this year. However, all of these biosimilars are in intravenous formulations, with no biosimilar subcutaneous options. It remains to be seen how deeply discounted these biosimilars will be, and whether those cost savings will be able to outweigh the benefits of a subcutaneous administration option.
Reference
Jackisch C, Stroyakovskiy D, Pivot X, et al. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial. JAMA Oncol. 2019;5(5):e190339. doi: 10.1001/jamaoncol.2019.0339.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.